THE GABA B AGONIST BACLOFEN REDUCES CIGARETTE CONSUMPTION IN A PRELIMINARY DOUBLE BLIND PLACEBO CONTROLLED SMOKING REDUCTION STUDY
Kaydedildi:
FRANKLIN, T.R., ET AL., THE GABA B AGONIST BACLOFEN REDUCES CIGARETTE CONSUMPTION IN A PRELIMINARY DOUBLE BLIND PLACEBO CONTROLLED SMOKING REDUCTION STUDY. DRUG AND ALCOHOL DEPENDENCE, Vol. 103, no. 1-2 (2009), p. 30-36.
Ref.
165148
Yer:
SIIS R.854 Archivo
Palabras clave:
Antagonistas, Ceguera, Drogodependencias, Evaluación, Fármacos, Programas de desintoxicación, Tabaco, Tabaquismo
Antagonistas, Ceguera, Drogodependencias, Evaluación, Fármacos, Programas de desintoxicación, Tabaco, Tabaquismo
Benzer Materyaller: THE GABA B AGONIST BACLOFEN REDUCES CIGARETTE CONSUMPTION IN A PRELIMINARY DOUBLE BLIND PLACEBO CONTROLLED SMOKING REDUCTION STUDY
- A PILOT DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF SERTRALINE WITH NALTREXONE IN THE TREATMENT OF OPIATE DEPENDENCE
- A PRELIMINARY TRIAL: DOUBLE-BLIND COMPARISON OF NEFAZODONE, DUPROPION-SR, AND PLACEBO IN THE TREATMENT OF CANNABIS DEPENDENCE
- A PHASE 3 PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTI-SITE TRIAL OF THE ALPHA-2-ADRENERGIC AGONIST, LOFEXIDINE, FOR OPIOID WITHDRAWAL
- DOUBLE-BLIND COMPARISON OF CARBAMAZEPINE AND PLACEBO FOR TREATMENT OF COCAINE DEPENDENCE
- OLANZAPINE IN COCAINE DEPENDENCE: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
- A DOUBLE BLIND, PLACEBO CONTROLLED, RANDOMIZED CLINICAL TRIAL OF ORAL SELEGILINE HYDROCHLORIDE FOR SMOKING CESSATION IN NICOTINE DEPENDENT CIGARETTE SMOKERS